Copy Link Print Information

Sorafenib

(Synonyms: Bay 43-9006)
307 Cited Publications
고객리뷰

Based on 307 publication(s) in Google Scholar

Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

  • Purity: 99.84%
  • CAS No.: 284461-73-0
  • 화학식: C21H16ClF3N4O3
  • 분자량:464.83
  • 보관:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 1 year , -20°C, 6 months
  • Sorafenib Chemical Structure
    Sorafenib Chemical Structure
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
  • Experimental Validation Results for Sorafenib
CAS No.: 284461-73-0
사이즈
가격
재고
수량
Amount: USD 0.00
Please select quantity
or
or

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Sorafenib:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
주변의 대리점 찾기 Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • 용액&용해도
  • 순도&문서
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Sorafenib

More
Customer Validation & Images
IHCCell Imaging/StainingWBHistological Imaging/StainingRT-PCRIn Vivo Efficacy StudyApoptosis AnalysisCell Migration/Invasion AssayBio/Physico-chemical Assay2D/3D Cell Culture and DifferentiationFlow CytometryELISAIFIn Vivo ImagingCell Proliferation/Viability Assay
  • In Vivo Efficacy Study
  • Bio/Physico-chemical Assay
  • Cell Imaging/Staining
  • ELISA
  • Cell Proliferation/Viability Assay
  • In Vivo Efficacy Study
  • IHC
  • Histological Imaging/Staining
  • Apoptosis Analysis
  • Cell Migration/Invasion Assay
  • Cell Imaging/Staining
  • Bio/Physico-chemical Assay
  • 2D/3D Cell Culture and Differentiation
  • Flow Cytometry
  • ELISA
  • IF
  • In Vivo Imaging
  • In Vivo Efficacy Study
  • WB
  • Cell Proliferation/Viability Assay
  • Cell Imaging/Staining
  • Bio/Physico-chemical Assay
  • Cell Proliferation/Viability Assay
  • Flow Cytometry
  • RT-PCR
  • WB
  • In Vivo Efficacy Study
  • IHC
  • Cell Proliferation/Viability Assay
  • Cell Imaging/Staining
  • Histological Imaging/Staining
  • Histological Imaging/Staining
  • Histological Imaging/Staining
  • In Vivo Efficacy Study
  • Cell Proliferation/Viability Assay
  • Flow Cytometry
  • In Vivo Efficacy Study
  • ELISA
  • RT-PCR
  • WB
  • WB
  • Flow Cytometry
  • Bio/Physico-chemical Assay
  • Cell Imaging/Staining
  • WB
  • IF
  • Cell Proliferation/Viability Assay
  • In Vivo Efficacy Study
  • IHC
  • WB
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • RT-PCR

All Raf Isoforms

More

All VEGFR Isoforms

More

All STAT Isoforms

More

All Akt Isoforms

More

All MMP Isoforms

More

All p38 MAPK Isoforms

More

All ERK Isoforms

More

All MEK Isoforms

More

All PI3K Isoforms

More

All PARP Isoforms

More

All Bcl-2 Family Isoforms

More
Keywords
MOQ
Minimum order quantity
100 mg

견적 받기 해외재고보유

Other size
견적 받기
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress 로그인
Register
Sign in to MedChemExpress
회원가입

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Sorafenib Chemical Structure
    Sorafenib Chemical Structure
    1/16
  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2026 Jun 4. [Abstract]

    Customer Validation
     Representative images of excised tumors and corresponding tumor weights in nude mice bearing HepG2-derived xenografts after oral Sorafenib (30 mg/kg/day; once daily for 19 d) or intraperitoneal nitidine treatment. sorafenib was used as a positive control.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2026 May:92:104086. [Abstract]

    Customer Validation
     Parental and Sora-R 769-P cells were treated with 30 μM sorafenib for 6 h, then quantified of GPX4 activity. GPX4 activity was markedly elevated in resistant cells.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2026 May:92:104086. [Abstract]

    Customer Validation
     Parental and Sora-R 769-P cells were treated with 30 μM Sorafenib for 6 h after pretreated with Tempol (50 μM), EUK-143 (50 μM), DFO (50 μM), and Fer-1 (1 μM) for 2 h, followed by quantification of lipid ROS using fluorescence microscope with C11-BODIPY 581/591 probe. Sorafenib-resistant cells exhibited significantly reduced lipid ROS compared with parental cells.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2026 May:92:104086. [Abstract]

    Customer Validation
     Parental and Sora-R 769-P cells were treated with 30 μM Sorafenib for 6 h after pretreated with DFO (50 μM) and Fer-1 (1 μM) for 2 h, followed by quantification of MDA via ELISA kits. Sorafenib-resistant cells showed decreased MDA levels.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2026 May:92:104086. [Abstract]

    Customer Validation
     Parental and Sora-R 769-P cells were treated with 10 μM GSK2643943A and 10 μM Sorafenib for 10 days, the colony number was measured with Image J.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Aug 21. [Abstract]

    Customer Validation
     Sorafenib (30 mg/kg; p.o.; once daily for 4 weeks). Tumor weight and volume of PDX #2 and PDX #3. Low-ARD1 PDX #2 responded better to Sorafenib monotherapy, whereas high-ARD1 PDX #3 showed a pronounced antitumor effect with combined AAV8-shARD1 and Sorafenib treatment.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Aug 21. [Abstract]

    Customer Validation
     Sorafenib (30 mg/kg; p.o.; once daily for 4 weeks). Representative immunohistochemical images of GCLC, 4-HNE and MDA in tumor tissues from NCG mice transplanted with PDX line #3. Combined AAV8-shARD1 and Sorafenib treatment increased 4-HNE and MDA expression more than either treatment alone.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Aug 21. [Abstract]

    Customer Validation
     C11-BODIPY staining of PDX #2 tumor tissues from NCG mice after Sorafenib (30 mg/kg; oral gavage; once daily for 4 weeks) and/or AAV8-shARD1 treatment to assess lipid peroxidation. PDX #2 showed increased basal fluorescence, which was further increased by Sorafenib alone irrespective of AAV8-shARD1 treatment.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]

    Customer Validation
     Annexin V-FITC/PI staining and flow cytometric analysis of Huh7 cells after treatment with Sv@PM-M2p containing SF (Sorafenib; 3 μM; 24 h). Sv@PM-M2p elevated percentage of dead cells.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]

    Customer Validation
     Transwell migration and invasion assays of Huh7 cells after treatment with Sv@PM-M2p containing SF (Sorafenib; 3 μM; 48 h). Sv@PM-M2p distinctly reduced the numbers of migrated and invaded Huh7 cells.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]

    Customer Validation
     TEM images of Huh7 cells after treatment with Sv@PM-M2p containing SF (Sorafenib; 3 μM; 24 h). Sv@PM-M2p caused mitochondrial shrinkage, decreased mitochondrial cristae, and increased mitochondrial membrane density.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]

    Customer Validation
     MDA levels in Huh7 cells after treatment with Sv@PM-M2p containing SF (Sorafenib; 3 μM; 24 h). Sv@PM-M2p promoted MDA accumulation.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]

    Customer Validation
     Fluorescence images of live/dead stained 1-6/TAM spheroids after treatment with Sv@PM-M2p containing SF (Sorafenib; 3 μM; 24 h). The penetration of Sv@PM-M2p triggered notable cell death within the spheroid.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]

    Customer Validation
     Flow cytometric analysis of anti-CRT-stained Hepa1-6 cells after treatment with Sv@PM-M2p containing SF (Sorafenib; 3 μM; 24 h). Sv@PM-M2p triggered the highest CRT expression on the cell surface.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]

    Customer Validation
     The HMGB1 assay of Hepa1-6 cells after treatment with Sv@PM-M2p containing SF (Sorafenib; 3 μM; 24 h).

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]

    Customer Validation
     Immunofluorescence images of tumor tissue slices collected from different groups stained with Liperfluo after different treatments. Mice were intravenously injected with SF (Sorafenib; 10 mg/kg; every 2 days for 14 d) and Sv@PM-M2p (10 mg/kg SF, wSF/wvF = 1.4/1). Sv@PM-M2p induced a significantly greater accumulation of LPO, particularly in NASH-driven HCC.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]

    Customer Validation
     Serial bioluminescence imaging and relative bioluminescence intensity of bilateral subcutaneous HCC mice after treatment with Sv@PM-M2p containing SF (Sorafenib; 10 mg/kg; i.v.; every 2 days for 10 d). Sv@PM-M2p significantly inhibited primary tumors and notably impacted tumor growth in distant metastatic tumors on the left flank.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]

    Customer Validation
     Collected tumor tissues and tumor weights of mice at the end of treatment in different groups. Mice were intravenously injected with SF (Sorafenib; 10 mg/kg; every 2 days for 14 d) and Sv@PM-M2p (10 mg/kg SF, wSF/wvF = 1.4/1). Sv@PM-M2p treatment resulted in pronounced tumor inhibition.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]

    Customer Validation
     Western blot analysis of GPX4 and FSP1 expression in tumor tissues after different treatments. Mice were intravenously injected with SF (Sorafenib; 10 mg/kg; every 2 days for 14 d), SF (10 mg/kg) + vF, Sv@PM-M2p (10 mg/kg SF, wSF/wvF = 1.4/1) and Sv@PM-M2p (10 mg/kg SF, wSF/wvF = 1.4/1) + Anti-PD-L1. Sv@PM-M2p most significantly reduced GPX4 and FSP1 expression in tumors.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 2;16(1):87. [Abstract]

    Customer Validation
     The cell viability of YAP-, YAP-S127A-, or YAP-R124F-overexpressed Huh-7 cells cultured in methionine-deprived medium (MD) and treated with sorafenib (1.5-3 μM) for 24 h.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Sep:85:103786. [Abstract]

    Customer Validation
     Control or ATF7IP knockdown HepG2 and Hep3B cells were treated with DMSO or Sorafenib (10 μM) for 48 h. ATF7IP knockdown increased the percentage of dead cells following Sorafenib treatment.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Sep:85:103786. [Abstract]

    Customer Validation
     Control or ATF7IP knockdown HepG2 cells were treated with DMSO or Sorafenib (10 μM) for 48 h. Relative levels of 4-HNE were analyzed by liquid chromatography-tandem mass spectrometry. ATF7IP knockdown elevated intracellular 4-HNE levels upon Sorafenib treatment.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Sep:85:103786. [Abstract]

    Customer Validation
     MTT assay in control or ATF7IP-knockdown HepG2 cells after Sorafenib treatment (10 μM; 48 h), in the absence or presence of DFO or Fer-1. Both inhibitors reversed the cell-viability changes induced by ATF7IP depletion upon Sorafenib treatment.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Sep:85:103786. [Abstract]

    Customer Validation
     Cellular lipid ROS was measured in control or ATF7IP-knockdown HepG2 cells after Sorafenib treatment (10 μM; 48 h), in the absence or presence of DFO or Fer-1. DFO and Fer-1 reversed the lipid ROS changes induced by ATF7IP depletion upon Sorafenib treatment.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Sep:85:103786. [Abstract]

    Customer Validation
     Control and ATF7IP knockdown HepG2 cells or SETDB1 knockdown HepG2 cells were treated with DMSO and Sorafenib (10 μM) for 48 h. RT-qPCR was performed to detect the mRNA expression levels of the indicated genes.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Sep:85:103786. [Abstract]

    Customer Validation
     Western blotting was used to detect the protein levels of PARK7 in control and ATF7IP knockdown HepG2 cells with DMSO or Sorafenib treatment (10 μM; 48 h). Upon ATF7IP depletion, PARK7 protein levels were significantly reduced under Sorafenib treatment.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Sep:85:103786. [Abstract]

    Customer Validation
     Endpoint xenograft images, tumor volumes and final tumor weights in mice bearing control, SETDB1-knockdown or ATF7IP-knockdown HepG2 tumors after Sorafenib treatment (20 mg/kg/day; i.g.; every other day for 40 d). SETDB1 or ATF7IP knockdown significantly suppressed tumor growth and reduced tumor volume and weight under Sorafenib treatment.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Sep:85:103786. [Abstract]

    Customer Validation
     Immunohistochemical staining and quantification of Ki-67 and CYB5R2 in control, SETDB1-knockdown orATF7IP-knockdown HepG2 xenografts after Sorafenib treatment (20 mg/kg/day; i.g.; every other day for 40 d). The protein level of CYBR2 was increased in SETDB1 and ATF7IP knockdown tumor tissues under Sorafenib treatment.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2024 Jul;5(7):1082-1101. [Abstract]

    Customer Validation
     Growth inhibition, IC50 and AUC values, of OCI-AML2 cells transduced with either a non-targeting control, two PIK3CG-directed, or two PIK3R5-directed sgRNAs and treated with increasing concentrations of the FLT3 inhibitors, Gilteritinib (10-1000 nM) and Sorafenib (10-1000 nM), or KIT inhibitors, Amuvanib and Telatinib

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]

    Customer Validation
     Sorafenib tosylate (90-900 nM) markedly suppressed the upregulation of endothelial-like differentiation in ligament cells mediated by LOXL2.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]

    Customer Validation
     Sorafenib tosylate (50 mg/kg; i.g.; one daily for 14 d) significantly decreased bone volume (BV) in BMP-induced ossification mice.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]

    Customer Validation
     Sorafenib tosylate (50 mg/kg; i.g.; once daily for 14 d) caused sparse trabecular bone structures in BMP-induced ossification mice, accompanied by numerous cartilage structures and amorphous matrix deposition, indicating a delay in endochondral ossification.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]

    Customer Validation
     Sorafenib tosylate (50 mg/kg; i.g.; once daily for 14 d) significantly lowered the level of SP7 in BMP-induced ossification mice.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Bone Res. 2024 Apr 10;12(1):24. [Abstract]

    Customer Validation
     Sorafenib tosylate (50 mg/kg; i.g.; once daily for 14 d)caused a shorter response time to thermal stimulation and less paw withdrawal threshold to mechanical stimulation of BMP-induced ossification mice.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 Dec:78:103419. [Abstract]

    Customer Validation
     Cell viability of the control NCI-H358, Calu-1, NCI-H23, MIA PaCa-2 and the corresponding resistant cell lines after 24 h of treatment with the indicated compounds. The resistant cells were more sensitive to Sorafenib (NCI-H358, NCI-H23 and MIA PaCa-2: 10 μM, Calu-1: 3 μM; 24 h).

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 Dec:78:103419. [Abstract]

    Customer Validation
     Flow cytometric analysis of oxidized BODIPY dye with quantified median fluorescence intensity in control NCI-H358, NCI-H23 and the corresponding resistant cell lines after Sorafenib treatment (10 μM; 24 h). Membrane lipid peroxidation was significantly increased in AR and MR cells after sorafenib treatment.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2024 Jan-Dec;16(1):2410474. [Abstract]

    Customer Validation
     Sorafenib (30 mg/kg; oral gavage; once daily for 14 d). Images of subcutaneous tumors, tumor volume, and tumor mass from hcc-bearing mouse model without ATBs pretreatment under different treatments.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2024 Jan-Dec;16(1):2410474. [Abstract]

    Customer Validation
     Sorafenib (30 mg/kg; oral gavage; once daily for 14 d). efm promoted the expression of ifn-γ and IL-12 in tumor tissues assessed by ELISA.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2024 Jan-Dec;16(1):2410474. [Abstract]

    Customer Validation
     SLC7A11 mRNA levels in tumor tissues with different treatment were detected by qRT-pcr analysis. The transcript levels of SLC7A11 in tumors were significantly decreased after combination treatment with Efm and Sorafenib (30 mg/kg; oral gavage; once daily for 14 d).

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: ACS Nano. 2023 Nov 28;17(22):22240-22258. [Abstract]

    Customer Validation
     Western blot to detect the ferritin H protein level by the gain or loss of URB1-AS1 in sorafenib-sensitive or sorafenib-resistant HepG2 cells.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: ACS Nano. 2023 Nov 28;17(22):22240-22258. [Abstract]

    Customer Validation
     qPCR showing the nuclear and cytoplasmic fractions of URB1-AS1 in sorafenib-resistant HepG2 cells with β-actin and MALAT1 as cytoplasmic and nuclear controls, respectively.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Feb:59:102564. [Abstract]

    Customer Validation
     Lipid peroxidation and intracellular ROS levels were detected using C11-BODIPY and DCFH-DA staining respectively, after treatment with 10 μM Sorafenib for 24 h in the absence or presence of 1 μM Fer-1. Treatment with Sorafenib led to an increase in total cellular ROS and lipid ROS compared to the control group.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Feb:59:102564. [Abstract]

    Customer Validation
     AGS and MGC-803 cells were incubated with 10 μM Sorafenib for 24 h in the absence or presence of 1 μM Fer-1, cellular MDA and GSH levels were detected. Incubation with sorafenib resulted in a dramatic increase in MDA but a decrease in GSH.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Feb:59:102564. [Abstract]

    Customer Validation
     The morphology of MGC803 cells was observed via TEM after treatment with 10 μM Sorafenib for 24 h in the absence or presence of 1 μM Fer-1. TEM revealed significantly decreased or absent mitochondrial cristae and increased mitochondrial membrane density in Sorafenib-treated MGC803 cells.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Feb:59:102564. [Abstract]

    Customer Validation
     The levels of ATF2, p-ATF2 and SLC7A11 proteins were assessed by western blot after treatment with10 μM Sorafenib (0-48 h) at the indicated time points in MGC803 cells. Sorafenib treatment increased ATF2 expression, especially the phosphorylated form.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Feb:59:102564. [Abstract]

    Customer Validation
     Immunofluorescence localization of ATF2 in AGS cells after treatment with or without 10 μM Sorafenib for 24 h. ATF2 was much more highly expressed in the nucleus upon stimulation with Sorafenib.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Feb:59:102564. [Abstract]

    Customer Validation
     The IC50 of GC cells after ATF2 overexpression and knockdown were determined using the CCK-8 assay. ATF2 overexpression increased the Sorafenib (0-80 μM; 24 h) IC50, whereas ATF2 knockdown decreased it.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Feb:59:102564. [Abstract]

    Customer Validation
     Tumor weight of the subcutaneous xenografts and growth curves of the tumor volume in the indicated groups. With Sorafenib (10 mg/kg; i.p.; every 2 days for 3 weeks) treatment, the volumes and weights of subcutaneous tumors were both significantly decreased.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Feb:59:102564. [Abstract]

    Customer Validation
     Representative immunohistochemistry images of ATF2 and 4-HNE expression in tumor tissues from the indicated groups. IHC staining showed that the expression of 4-HNE in the sh-ATF2 + Sorafenib (10 mg/kg; i.p.; every 2 days for 3 weeks) group was the highest.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Oct;13(10):4253-4272. [Abstract]

    Customer Validation
     PANC-1 cells were transfected with the recombinant plasmid for 24 h and treated with sorafenib (0–70 μmol/L) for another 24 h, and then total cellular extracts were subjected to Western blotting using antibodies against caspase-3, GSDME and β-tubulin.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Jun;13(6):2645-2662. [Abstract]

    Customer Validation
     HeLa and SiHa cells were treated with condition medium (CM) from human PBMC-derived M0 macrophages (Ctrl) and TAM. And then cells were treated with indicated dose of Sorafenib (Sora) for 48 h. Inhibition ratio of cell viability was detected by CCK-8 assay.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Oct;13(10):4253-4272. [Abstract]

    Customer Validation
     Sorafenib (12.5-125 μM; 24 h) inhibits the viability of PANC-1 cells in a dose-dependent manner.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Discov Oncol. 2023 May 27;14(1):83. [Abstract]

    Customer Validation
     Sorafenib (0.25, 0.5, 1, 2, 4, 6 µM; 24 h) significantly inhibits the cell viability of HepG2 and Hep3B.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Discov Oncol. 2023 May 27;14(1):83. [Abstract]

    Customer Validation
     Sorafenib (3 µM; 24 h) significantly inhibits the cell proliferation of HepG2 and Hep3B.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2021 Oct;11(10):2544-2563. [Abstract]

    Customer Validation
     Sorafenib (10 nM-10 μM; 72 h). Dose response curve of drugs tested in triplicate against cells from PDX (FLC1-6) and PHH.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2018 Apr 25;14(5):577-585. [Abstract]

    Customer Validation
     Hep3B, HepG2 and Huh7 cells are treated with 5 μM Sorafenib. The expressing levels of JAK1, JAK2, STAT3, SHP1, SHP2, actin and phosphorylation levels of STAT3 are determined by western blot using the antibodies, respectively.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2018 Sep;40(3):1525-1532. [Abstract]

    Customer Validation
     SMMC-7721 and HepG2 cells are treated with 4 µM Sorafenib and 100 µM Berberine alone or in combination (4 µM Sorafenib+100 µM Berberine) for 72 h, and the expression levels of apoptosis-associated proteins are measured by western blot analysis.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Br J Cancer. 2017 Sep 26;117(7):974-983. [Abstract]

    Customer Validation
     The effect of the AKT inhibitor MK2206 (10 μM) on the expression levels of phosphor-AKT, AKT, and STMN1 in TKI-pretreated NCI-H460 cells. β-actin is used as a loading control.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: J Pharmacol Exp Ther. 2017 Aug;362(2):219-229. [Abstract]

    Customer Validation
     The combination of sorafenib and CAI induces apoptosis in NSCLC. Effect of 10 μM CAI and/or 5 μM Sorafenib on the expression of cleaved PARP and cleaved caspase-. Protein levels of cleaved PARP and cleaved caspase-3 from treated cell lysates are normalized against GAPDH levels.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2017 Dec 1;7(12):2503-2514. [Abstract]

    Customer Validation
     VPA potentiates anti-tumor effects of Sorafenib tosylate in vivo. The expression of cleaved caspase9, cleaved caspase3, cleaved PARP from tumor tissue homogenates are analyzed by western blot.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Endocr J. 2017 Nov 29;64(11):1115-1123. [Abstract]

    Customer Validation
     Effect of Sorafenib on phosphorylation of ERK and AKT. Thyroid cancer cells are treated for 30 minutes with 10 μM Sorafenib, 10 μM Forskolin, and combination therapy of 10 μM Sorafenib with 10 μM Forskolin. The levels of ERK and AKT phosphorylation are examined by immunoblot analysis. β-actin is used as the control. Sorafenib suppresses phosphorylation of ERK, but not of AKT.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Endocr J. 2017 Nov 29;64(11):1115-1123. [Abstract]

    Customer Validation
     Effect of Sorafenib and Forskolin on expression of CDK4 and CDK regulatory proteins. Thyroid cancer cells are treated for 24 hours with 10 μM Sorafenib, 10 μM Forskolin, and combination therapy of 10 μM Sorafenib with 10 μM Forskolin. The expression of cyclin D1, CDK4, and phosphorylation of RB are examined by immunoblot analysis. β-actin is used as the control. The combination therapy suppresses expression of cyclin D1, and Forskolin monotherapy suppresses expression of cyclin D1 in TPC-1 and W

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 May 2;8(18):29771-29784. [Abstract]

    Customer Validation
     Sorafenib inhibits Pin1 biosynthesis and accumulation in Huh7 and HepG2 cells. Cells are treated with 5 or 10 μM Sorafenib for indicated times. Pin1 protein expression is determined by Western Blot.

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81. [Abstract]

    Customer Validation
     The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/SU 11248 (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by Western blot (with GAPDH as internal control).

  • 1/16

    Sorafenib purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81. [Abstract]

    Customer Validation
     The relationship between SOX9 and Raf/MEK/ERK signaling pathway. Co-treatment of si-SOX9-1 and Sorafenib (10uM, 15uM)/SU 11248 (2 uM, 3 uM) significantly decreases expression of MEK1 and its phosphorylated protein (p-MEK1/2, p-ERK1/2) as assayed by RT-PCR (with β-actin as internal control).

  • Sorafenib